Last reviewed · How we verify
0.15% Brimonidine Tartrate
At a glance
| Generic name | 0.15% Brimonidine Tartrate |
|---|---|
| Also known as | Alphagan® P |
| Sponsor | Allergan |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients (PHASE4)
- Brimonidine for Intraoperative Hemostasis (PHASE4)
- Superior vs Temporal Laser Peripheral Iridotomy in Primary Angle Closure Suspects (PACS) (NA)
- Brimonidine Tartrate for Pterygium Surgery (NA)
- Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN-T Eye Drops 0.15% and ALPHAGAN-P Eye Drops 0.15% in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Multi-center Trial (PHASE4)
- Brimonidine for Subconjunctival Hemorrhage From Femtosecond Laser Assisted Cataract Surgery (NA)
- Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD) (PHASE1, PHASE2)
- Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 0.15% Brimonidine Tartrate CI brief — competitive landscape report
- 0.15% Brimonidine Tartrate updates RSS · CI watch RSS
- Allergan portfolio CI